Figure 4.
Figure 4. GVHD prophylaxis preserved ovarian functions and fertility. (A-D) Mice were transplanted as in Figure 1A-D, followed by the oral administration of 10 mg/kg PSL daily from day 0 to day +20. (A) Clinical GVHD scores on day +21 of diluent-treated (n = 6) and PSL-treated (n = 6) syngeneic recipients and diluent-treated (n = 13) and PSL-treated (n = 8) allogeneic recipients are shown as mean ± SE. (B) The ovary isolated on day +14 was stained with anti-CD3 mAbs (brown). Original magnification ×20. Scale bar, 100 µm. (C) Serum levels of AMH in diluent-treated (n = 6) and PSL-treated (n = 6) syngeneic recipients, and diluent-treated (n = 13) and PSL-treated (n = 8) allogeneic recipients, are shown as mean ± SE. (D) Numbers of oocytes ovulated on stimulation with PMSG and hCG in diluent-treated (n = 5) and PSL-treated (n = 4) syngeneic recipients and diluent-treated (n = 7) and PSL-treated (n = 6) allogeneic recipients are shown as means ± SE. (E) Recipients were orally treated with 10 mg/kg PSL daily from day 0 to day +14, and thrice a week thereafter. Recipients were mated with naive B6D2F1 males repeatedly from day +14 to day +150 after SCT. Total numbers of newborns delivered by day +150 from diluent-treated (n = 5) and PSL-treated (n = 5) syngeneic recipients and diluent-treated (n = 10) and PSL-treated (n = 10) allogeneic recipients. (F-H) 100 mg/kg CSP was orally given to the recipients on days 0 to +20 after SCT (n = 4-9 /group). Clinical GVHD scores (F), serum levels of AMH (G), and numbers of oocytes on ovulation induction (H) in diluent-treated (n = 7) and CSP-treated (n = 12) syngeneic recipients and diluent-treated (n = 7) and CSP-treated (n = 13) allogeneic recipients from 2 independent experiments are combined and shown as means ± SE. (I-K) 5 mg/kg TAC was orally given to the recipients on days 0 to +20 after SCT. Clinical GVHD scores (I) and serum levels of AMH (J) in diluent-treated (n = 5) and TAC-treated (n = 6) syngeneic recipients and diluent-treated (n = 4) and TAC-treated (n = 6) allogeneic recipients are shown as means ± SE. (K) The numbers of oocytes on ovulation induction in diluent-treated (n = 5) and TAC-treated (n = 4) syngeneic recipients and diluent-treated (n = 2) and TAC-treated (n = 4) allogeneic recipients are shown. *P < .05, **P < .01, ***P < .005.

GVHD prophylaxis preserved ovarian functions and fertility. (A-D) Mice were transplanted as in Figure 1A-D, followed by the oral administration of 10 mg/kg PSL daily from day 0 to day +20. (A) Clinical GVHD scores on day +21 of diluent-treated (n = 6) and PSL-treated (n = 6) syngeneic recipients and diluent-treated (n = 13) and PSL-treated (n = 8) allogeneic recipients are shown as mean ± SE. (B) The ovary isolated on day +14 was stained with anti-CD3 mAbs (brown). Original magnification ×20. Scale bar, 100 µm. (C) Serum levels of AMH in diluent-treated (n = 6) and PSL-treated (n = 6) syngeneic recipients, and diluent-treated (n = 13) and PSL-treated (n = 8) allogeneic recipients, are shown as mean ± SE. (D) Numbers of oocytes ovulated on stimulation with PMSG and hCG in diluent-treated (n = 5) and PSL-treated (n = 4) syngeneic recipients and diluent-treated (n = 7) and PSL-treated (n = 6) allogeneic recipients are shown as means ± SE. (E) Recipients were orally treated with 10 mg/kg PSL daily from day 0 to day +14, and thrice a week thereafter. Recipients were mated with naive B6D2F1 males repeatedly from day +14 to day +150 after SCT. Total numbers of newborns delivered by day +150 from diluent-treated (n = 5) and PSL-treated (n = 5) syngeneic recipients and diluent-treated (n = 10) and PSL-treated (n = 10) allogeneic recipients. (F-H) 100 mg/kg CSP was orally given to the recipients on days 0 to +20 after SCT (n = 4-9 /group). Clinical GVHD scores (F), serum levels of AMH (G), and numbers of oocytes on ovulation induction (H) in diluent-treated (n = 7) and CSP-treated (n = 12) syngeneic recipients and diluent-treated (n = 7) and CSP-treated (n = 13) allogeneic recipients from 2 independent experiments are combined and shown as means ± SE. (I-K) 5 mg/kg TAC was orally given to the recipients on days 0 to +20 after SCT. Clinical GVHD scores (I) and serum levels of AMH (J) in diluent-treated (n = 5) and TAC-treated (n = 6) syngeneic recipients and diluent-treated (n = 4) and TAC-treated (n = 6) allogeneic recipients are shown as means ± SE. (K) The numbers of oocytes on ovulation induction in diluent-treated (n = 5) and TAC-treated (n = 4) syngeneic recipients and diluent-treated (n = 2) and TAC-treated (n = 4) allogeneic recipients are shown. *P < .05, **P < .01, ***P < .005.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal